Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

Publication | Open Access

DOI Full Paper Access

173

Citations

References

2024

Year

Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Ke‐Neng Chen, Christophe Dooms, Margarita Majem,

The Lancet

OncologyAdjuvant PembrolizumabClinical TrialsImmune Checkpoint InhibitorNeoadjuvant PembrolizumabCancer TreatmentMedicineRadiation OncologyLung CancerNeoadjuvant ChemotherapyHealth Sciences